Grant: Engage Plus Grants Program
University of Waterloo
$12,500.00
Optimization of a Mammalian Cell Bioprocess using a Semi-Mechanistic Model
EF 2017-18
Résumé
Chinese hamster ovary (CHO) cells are used extensively in the pharmaceutical industry to produce recombinantproteins to treat an array of diseases. The productivity and the therapeutic effectiveness of these proteins arehighly influenced by the chemical composition of the chemical medium and the bioreactor operating conditionsthat are used to grow the cells.Optimizing the media composition is very challenging due to its complex nature involving tens of differentcomponents such as aminoacids and non-aminoacid species (salts, vitamins, metals etc.).Our industrial collaborator (Sigma-Aldrich), a main manufacturer of cell culture media, is currentlyexperimenting with an advanced system of 48 micro-reactors (Sartorius-AMBR 15, 15 ml volume each), that itis not available in our lab, to develop new cell lines and growth media. Although industrial antibodymanufacturing involves either fed-batch or perfusion operations, the AMBR micro-bioreactor system iscomparatively much easier, quicker and cheaper to run for the purpose of media development.The work of my group in modeling of mammalian cells (Nikdel and Budman, 2016) can be directly applied totwo aspects that are of interest for Sigma for the purpose of media development with the AMBR system:i- To expand the validity of the model developed at Waterloo under the first Engage project for describing bothAMBR and perfusion operations using different media formulations andii- To develop a novel hybrid modeling approach, where the metabolic model describing the dynamics ofaminoacids is combined with an empirical model to describe non-aminoacid components (salts, vitamins,metals, etc.). This model will be later used for media and process optimization.
Programme
Engage Plus Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
514389-2017
Name nom
Budman, Hector
Department département
Chemical Engineering
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
12500
Program id
EGP2
Program name en
Engage Plus Grants Program
Program name fr
Programme de subvention d'engagement partenarial Plus
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1800
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Chemical engineering
Research subject fr
Génie chimique
Partie
1
Nb partie
1
Application title
Optimization of a Mammalian Cell Bioprocess using a Semi-Mechanistic Model
Keyword
NSERC
Application summary
Chinese hamster ovary (CHO) cells are used extensively in the pharmaceutical industry to produce recombinantproteins to treat an array of diseases. The productivity and the therapeutic effectiveness of these proteins arehighly influenced by the chemical composition of the chemical medium and the bioreactor operating conditionsthat are used to grow the cells.Optimizing the media composition is very challenging due to its complex nature involving tens of differentcomponents such as aminoacids and non-aminoacid species (salts, vitamins, metals etc.).Our industrial collaborator (Sigma-Aldrich), a main manufacturer of cell culture media, is currentlyexperimenting with an advanced system of 48 micro-reactors (Sartorius-AMBR 15, 15 ml volume each), that itis not available in our lab, to develop new cell lines and growth media. Although industrial antibodymanufacturing involves either fed-batch or perfusion operations, the AMBR micro-bioreactor system iscomparatively much easier, quicker and cheaper to run for the purpose of media development.The work of my group in modeling of mammalian cells (Nikdel and Budman, 2016) can be directly applied totwo aspects that are of interest for Sigma for the purpose of media development with the AMBR system:i- To expand the validity of the model developed at Waterloo under the first Engage project for describing bothAMBR and perfusion operations using different media formulations andii- To develop a novel hybrid modeling approach, where the metabolic model describing the dynamics ofaminoacids is combined with an empirical model to describe non-aminoacid components (salts, vitamins,metals, etc.). This model will be later used for media and process optimization.